IOVA — IOVANCE BIOTHERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1425205 ·
Last close
$11.00
Market Cap
$4.98B
52W High
$11.13
52W Low
$1.76
ADV30
15,283,310
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 71,430,000 | 28,932,000 | -81,043,000 | -79,045,000 | 925,665,000 | 196,508,000 | 203,911,000 |
| Dec 2025 | 86,771,000 | 43,660,000 | -73,460,000 | -71,904,000 | 913,170,000 | 163,078,000 | 214,587,000 |
| Sep 2025 | 67,455,000 | 28,978,000 | -89,758,000 | -91,253,000 | 904,948,000 | 158,134,000 | 202,661,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-270,788,000
Investing CF
$43,023,000
Financing CF
$251,793,000
CapEx
$-34,233,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,854,575,000
Inventory
$58,376,000
Receivables
$81,758,000
ST Investments
$116,935,000
EBIT TTM
$-358,035,000
Pretax Income TTM
$-354,758,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$324,968,992
EBITDA
$-259,603,008
Free Cash Flow
$-187,794,752
Enterprise Value
$3,643,885,312
Total Cash
$297,673,984
Total Debt
$46,003,000
Shares Out
452,971,432
Trailing EPS
$-0.69
Book Value
$1.62
ROE
-40.4%
ROA
-20.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 263,502,000 | -398,213,000 | -390,978,000 | 913,170,000 | 214,587,000 | 698,583,000 | -302,408,000 |
| Dec 2024 | 164,070,000 | -395,278,000 | -372,177,000 | 910,426,000 | 200,021,000 | 710,405,000 | -352,977,000 |
| Dec 2023 | 1,189,000 | -460,559,000 | -444,037,000 | 780,351,000 | 195,738,000 | 584,613,000 | -361,820,000 |
| Dec 2022 | 0 | -398,878,000 | -395,893,000 | 663,982,000 | 164,344,000 | 499,638,000 | -292,757,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.29
Max Pain — expiry 2026-10-02
max pain strike: $10.50 · spot: $11.06 · call oi: 7,696 · put oi: 6,088
Expected Move to 2026-10-02:
±$0.98
(8.81%) —
implied range
$10.09 –
$12.04
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $5.24B | $54.23 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.70B | $29.43 | — |
| SRRK | Scholar Rock Holding Corp | $5.92B | $48.63 | — |
| CGON | CG Oncology, Inc. | $5.95B | $67.15 | — |
| RLAY | Relay Therapeutics, Inc. | $3.83B | $17.47 | — |
News headlines (Yahoo Finance, 1h cache)
Why Iovance Biotherapeutics Stock Was on Fire Today
2026-09-25 00:17 · Yahoo
Why Did Iovance Biotherapeutics (IOVA) Move Today?
2026-09-19 22:15 · Yahoo
Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion
2026-09-19 18:08 · Yahoo
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
2026-09-19 11:02 · Yahoo
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-09-18 21:10 · Yahoo
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
2026-09-17 07:21 · Yahoo
IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’
2026-09-15 23:01 · Yahoo
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
2026-09-15 04:00 · Yahoo
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
2026-08-27 08:27 · Yahoo
Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin Progress
2026-09-19 16:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.